ACE

Across TCGA pan-cancer cohorts, ACE Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACE data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ACE Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACE expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, PAAD, and BLCA are the cancer types where ACE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.123	0.796	<.001	36	view →
PAAD	OS	Median	All	0.110	0.640	<.001	24	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
UCEC	DFS	Median	All	0.932	0.607	.008	12	view →
TGCT	DFS	Median	II,III,IV	0.088	0.917	.010	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACE–KIRC (DFS)

Open the KIRC breakdown →